Summary
4.17 0.06(1.34%)05/09/2024
Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc (AUTL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.72 | 8.97 | -26.15 | -36.55 | 8.97 | 113.30 | -84.14 | -83.96 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.01 | |
| Open | 4.08 | |
| High | 4.16 | |
| Low | 3.98 | |
| Volume | 2,001,208 | |
| Change | -0.07 | |
| Change % | -1.72 | |
| Avg Volume (20 Days) | 2,654,675 | |
| Volume/Avg Volume (20 Days) Ratio | 0.75 | |
| 52 Week Range | 1.79 - 7.45 | |
| Price vs 52 Week High | -46.17% | |
| Price vs 52 Week Low | 124.02% | |
| Range | -1.72 | |
| Gap Up/Down | -0.24 | |
Fundamentals | ||
| Market Capitalization (Mln) | 726 | |
| EBIDTA | -68,942,608 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 15.06 | |
| Book Value | 3.3560 | |
| Earnings Per Share | -2.2170 | |
| EPS Estimate Current Quarter | -0.5100 | |
| EPS Estimate Next Quarter | -0.5100 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | -2.2170 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -64.4511 | |
| Return on asset (TTM) | -0.3353 | |
| Return on equity (TTM) | -0.5951 | |
| Revenue TTM | 2,554,000 | |
| Revenue per share TTM | 0.0400 | |
| Quarterly Revenue Growth (YOY) | -0.6530 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -133,173,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.0470 | |
| Revenue Enterprise Value | 232.0527 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 72,742,600 | |
| Shares Float | 36,755,548 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 25.23 | |
| Institutions (%) | 59.27 | |
02/29 07:00 EST - GlobeNewsWire
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights on Thursday March 14, 2024. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company's financial results and provide a general business update.
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it will release its fourth quarter and full year 2023 results and operational highlights on Thursday March 14, 2024. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company's financial results and provide a general business update.
02/12 03:31 EST - Zacks Investment Research
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
Autolus Therapeutics PLC Sponsored ADR (AUTL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
02/06 09:52 EST - Seeking Alpha
Autolus Upgrades Leadership And Faces CAR-T Approval
Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies. Thus, the company will likely gain its first market authorization in November. Autolus made several strong leadership hires with direct experience in M&A, oncology, and lupus, a new research area.
Autolus Upgrades Leadership And Faces CAR-T Approval
Obe-cel continues to demonstrate comparative efficacy with fewer side effects to approved therapies. Thus, the company will likely gain its first market authorization in November. Autolus made several strong leadership hires with direct experience in M&A, oncology, and lupus, a new research area.
02/02 21:26 EST - InvestorPlace
The Jobs Report Blows Away Forecasts
January's payrolls report shows 353,000 jobs
The Jobs Report Blows Away Forecasts
January's payrolls report shows 353,000 jobs
12/18 04:12 EST - Seeking Alpha
Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast
Autolus Therapeutics is developing cell-based immunotherapy for cancer, focusing on CD19 in ALL. Their flagship product, obe-cel, has shown promising results in treating relapsed/refractory B-cell ALL with reduced toxicities compared to other CAR T-cell therapies. Autolus Therapeutics also has a dual-targeted BCMA/CD19 CAR T-cell therapy called AUTO8, which has shown positive responses in patients with relapsed/refractory multiple myeloma.
Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast
Autolus Therapeutics is developing cell-based immunotherapy for cancer, focusing on CD19 in ALL. Their flagship product, obe-cel, has shown promising results in treating relapsed/refractory B-cell ALL with reduced toxicities compared to other CAR T-cell therapies. Autolus Therapeutics also has a dual-targeted BCMA/CD19 CAR T-cell therapy called AUTO8, which has shown positive responses in patients with relapsed/refractory multiple myeloma.
11/06 07:00 EST - GlobeNewsWire
Autolus Therapeutics announces participation in upcoming conferences
LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November. Truist Securities BioPharma Symposium Panel : Considerations for an Oncology Company's Autoimmune Side Hustle Date and time: 9 November 2023, 11:40am ET / 16:40pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Jefferies London Healthcare Conference Fireside Chat Date and time: 16 November 2023, 4:00am ET / 9:00am GMTLocation: London, UKPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Piper Sandler 35th Annual Healthcare Conference Fireside Chat Date and time: 28 November 2023, 11:30am ET/ 16:30pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/ About Autolus Therapeutics plc Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease.
Autolus Therapeutics announces participation in upcoming conferences
LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November. Truist Securities BioPharma Symposium Panel : Considerations for an Oncology Company's Autoimmune Side Hustle Date and time: 9 November 2023, 11:40am ET / 16:40pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Jefferies London Healthcare Conference Fireside Chat Date and time: 16 November 2023, 4:00am ET / 9:00am GMTLocation: London, UKPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Piper Sandler 35th Annual Healthcare Conference Fireside Chat Date and time: 28 November 2023, 11:30am ET/ 16:30pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/ About Autolus Therapeutics plc Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease.
11/03 22:05 EST - Seeking Alpha
Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Matthew Phipps – William Blair Dev Prasad – Jefferies Gil Blum – Needham and Company Yanan Zhu – Wells Fargo Karina Rabayeva – Truist Simon Baker – Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Third Quarter 2023 Financial Results Conference Call and Business Update. At this time, all participants are in listen-only mode.
Autolus Therapeutics plc (AUTL) Q3 2023 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Julia Wilson – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Matthew Phipps – William Blair Dev Prasad – Jefferies Gil Blum – Needham and Company Yanan Zhu – Wells Fargo Karina Rabayeva – Truist Simon Baker – Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Third Quarter 2023 Financial Results Conference Call and Business Update. At this time, all participants are in listen-only mode.
10/11 08:07 EST - GlobeNewsWire
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company's financial results and provide a general business update.
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company's financial results and provide a general business update.
10/11 07:00 EST - GlobeNewsWire
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company's financial results and provide a general business update.
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company's financial results and provide a general business update.
08/06 07:59 EST - Seeking Alpha
Autolus Therapeutics plc (AUTL) Q2 2023 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Dr. Christian Itin - CEO Dr. Lucinda Crabtree - CFO Rob Dolski - incoming CFO Julia Wilson - IR Conference Call Participants Matt Phipps - William Blair Asthika Goonewardene - Truist Financial Kelly Shi - Jefferies Noah Burhance - J.P. Morgan Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Second Quarter 2023 Financial Results Conference.
Autolus Therapeutics plc (AUTL) Q2 2023 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Dr. Christian Itin - CEO Dr. Lucinda Crabtree - CFO Rob Dolski - incoming CFO Julia Wilson - IR Conference Call Participants Matt Phipps - William Blair Asthika Goonewardene - Truist Financial Kelly Shi - Jefferies Noah Burhance - J.P. Morgan Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Second Quarter 2023 Financial Results Conference.
07/18 07:00 EST - GlobeNewsWire
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2023 financial results and operational highlights before open of US markets on Thursday, August 3, 2023.
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2023 financial results and operational highlights before open of US markets on Thursday, August 3, 2023.
06/30 19:34 EST - Seeking Alpha
Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket
Obe-cel and pipeline offer many catalysts in 2023. The CAR T-cell candidate offer a safer alternative to commercial rivals. Strong cash position should see the company through to obe-cel launch.
Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket
Obe-cel and pipeline offer many catalysts in 2023. The CAR T-cell candidate offer a safer alternative to commercial rivals. Strong cash position should see the company through to obe-cel launch.
06/14 09:39 EST - InvestorPlace
3 Top Penny Stock Picks You Haven't Heard Of
Unless you regularly invest in or research penny stocks it's likely you aren't familiar with most companies in the space. These penny stock picks aren't household names because by and large they aren't big companies and their products and services are largely foreign to consumers.
3 Top Penny Stock Picks You Haven't Heard Of
Unless you regularly invest in or research penny stocks it's likely you aren't familiar with most companies in the space. These penny stock picks aren't household names because by and large they aren't big companies and their products and services are largely foreign to consumers.
04/20 07:00 EST - GlobeNewsWire
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2023 financial results and operational highlights before open of U.S. markets on Thursday, May 4, 2023.
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2023 financial results and operational highlights before open of U.S. markets on Thursday, May 4, 2023.
03/07 14:04 EST - Seeking Alpha
Autolus Therapeutics (AUTL) Q4 2022 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Julia Wilson - Consilium Strategic Advisors Conference Call Participants Gil Blum - Needham & Co. Mara Goldstein - Mizuho Group Matthew Phipps - William Blair Kelly Shi - Jefferies James Shin - Wells Fargo Sebastiaan van der Schoot - Van Lanschot Kempen Karina Rabayeva - Truist Securities Operator Ladies and gentlemen, welcome to the Autolus Therapeutics full year 2022 financial results conference call and fourth quarter operational progress. As a reminder, this conference is being recorded.
Autolus Therapeutics (AUTL) Q4 2022 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Julia Wilson - Consilium Strategic Advisors Conference Call Participants Gil Blum - Needham & Co. Mara Goldstein - Mizuho Group Matthew Phipps - William Blair Kelly Shi - Jefferies James Shin - Wells Fargo Sebastiaan van der Schoot - Van Lanschot Kempen Karina Rabayeva - Truist Securities Operator Ladies and gentlemen, welcome to the Autolus Therapeutics full year 2022 financial results conference call and fourth quarter operational progress. As a reminder, this conference is being recorded.
02/15 07:00 EST - GlobeNewsWire
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2022 financial results and operational highlights before open of U.S. markets on Tuesday, March 7, 2023.
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2022 financial results and operational highlights before open of U.S. markets on Tuesday, March 7, 2023.
12/12 10:00 EST - GlobeNewsWire
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three posters with updates from three Phase 1 clinical trials to be presented at the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2022.
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three posters with updates from three Phase 1 clinical trials to be presented at the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2022.
12/09 11:31 EST - The Motley Fool
Why Autolus Therapeutics Stock Is Crashing Today
The biopharmaceutical company announced the pricing of a secondary stock offering.
Why Autolus Therapeutics Stock Is Crashing Today
The biopharmaceutical company announced the pricing of a secondary stock offering.
11/16 06:21 EST - Seeking Alpha
Autolus Therapeutics: Near-Term Catalyst Plus Several Bio Deals Could Shift Momentum
Results from the pivotal FELIX phase 2 clinical study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia expected in Q4 of 2022. With positive results, a Biologics Licensing Application of obe-cel for the treatment of patients with r/r B-cell ALL is expected by end of 2023.
Autolus Therapeutics: Near-Term Catalyst Plus Several Bio Deals Could Shift Momentum
Results from the pivotal FELIX phase 2 clinical study using obe-cel for the treatment of patients with relapsed/refractory Acute Lymphoblastic Leukemia expected in Q4 of 2022. With positive results, a Biologics Licensing Application of obe-cel for the treatment of patients with r/r B-cell ALL is expected by end of 2023.
11/04 22:15 EST - Seeking Alpha
Autolus Therapeutics plc (AUTL) Q3 2022 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Conference Call Participants Mara Goldstein - Mizuho Matthew Phipps - William Blair James Shin - Wells Fargo Securities Gil Blum - Needham & Company Operator Hello ladies and gentlemen and welcome to the Autolus Therapeutics Third Quarter 2022 Financial Results Conference Call. As a reminder, this conference call is being recorded.
Autolus Therapeutics plc (AUTL) Q3 2022 Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Conference Call Participants Mara Goldstein - Mizuho Matthew Phipps - William Blair James Shin - Wells Fargo Securities Gil Blum - Needham & Company Operator Hello ladies and gentlemen and welcome to the Autolus Therapeutics Third Quarter 2022 Financial Results Conference Call. As a reminder, this conference call is being recorded.